jagx stock — Jaguar Health guide

This article explains jagx stock (Jaguar Health, Inc., ticker JAGX) including the company profile, products (Mytesi/crofelemer), corporate structure, stock listing details, recent news as of Jan 26...

2024-07-09 00:30:00

By Crypto Scribe

Article rating

4.7

103 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Jaguar Health, Inc. (jagx stock)

Keyword note: this article uses the exact phrase "jagx stock" throughout to match common search queries and help readers find authoritative, beginner-friendly information about Jaguar Health and its publicly traded shares.

Quick introduction

jagx stock refers to the publicly traded common equity of Jaguar Health, Inc., which is listed on the Nasdaq under the ticker JAGX. This guide summarizes Jaguar Health’s business focus (plant-derived gastrointestinal products), key marketed products, clinical pipeline, corporate and share-structure details, recent public developments (with reporting dates), financial highlights, and the primary risks investors commonly evaluate when researching a small-cap clinical-stage pharmaceutical company. Expect clear definitions, citations to mainstream market-data providers, and pointers to official SEC filings and the company’s investor materials.

As of Jan 26, 2026, per major market-data providers (see References), jagx stock remains classified as a micro-cap equity and is frequently discussed in retail trading communities and specialized biotech coverage. This article is informational and not investment advice.

Company overview

Jaguar Health, Inc. is a commercial-stage biotechnology and pharmaceutical company focused on plant-derived gastrointestinal therapeutics. The company develops and commercializes products for human and animal gastrointestinal disorders, leveraging a proprietary plant-based compound, crofelemer, as its lead active ingredient. Jaguar Health operates in two main business segments: Human Health (commercial sales and licensing of crofelemer/Mytesi) and Animal Health (veterinary product development and licensing).

Founded: Jaguar Health traces its commercial activities and corporate identity to the company that advanced crofelemer into clinical development and commercialization. For full founding and historical details, consult the company’s SEC filings and the corporate "About Us" page.
Headquarters: The company lists its principal executive offices in the United States. (See company filings for the exact address.)
Business model: commercial sales paired with licensing and partnership revenues for human and animal indications.

Sources for corporate history and profile include the company’s investor relations materials and Nasdaq company page. Where the term jagx stock appears below, it denotes shares of Jaguar Health traded publicly under the JAGX ticker.

Products and pipeline

Marketed product(s)

Mytesi (crofelemer): Crofelemer is the active compound in Mytesi, an oral botanical agent approved by the U.S. Food and Drug Administration for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Jaguar Health has held commercial rights to crofelemer-based products and has pursued additional indications and formulations. jagx stock valuation and investor interest are materially influenced by the commercial performance and licensing prospects of Mytesi.

Veterinary and animal health products

Canalevia-CA1 and similar veterinary candidates: Jaguar Health has pursued animal-health development and licensing strategies to broaden crofelemer’s applications. Animal health programs aim to create additional revenue streams beyond human therapeutics and are part of the company’s strategic diversification that can affect jagx stock sentiment.

Clinical-stage assets

Crofelemer development programs: Beyond Mytesi’s approved human indication, Jaguar Health has evaluated crofelemer for other gastrointestinal indications and formulations. Clinical-stage assets and preclinical candidates (often referenced under program names such as NP-300 in some corporate materials) may be subject to trials, regulatory designations, or partnering discussions. Progress or setbacks in these programs are typical binary catalysts for jagx stock.

Note: For exact program names, trial identifiers, and regulatory status, consult the company’s clinical-trial disclosures and recent 10-Q/8-K filings.

Corporate structure and management

Jaguar Health’s corporate governance consists of an executive team and a board of directors responsible for clinical strategy, commercialization, and corporate finance. Key governance points that investors monitor include the CEO, board chair, and any members with pharmaceutical or animal-health expertise. Insider ownership and board composition can materially affect views on jagx stock because concentrated insider holdings or active insider transactions influence available float and perceived alignment with shareholders.

Executive leadership: The company’s chief executive officer and other named executives are disclosed in annual reports and proxy statements. These officers oversee research & development, commercial operations, and finance.
Employees: Jaguar Health is a small to mid-size team typical of micro-cap biotechs; employee counts and headcount trends appear in annual SEC filings.
Governance highlights: Investors evaluate independence of board members, audit and compensation committee makeup, and any special arrangements or recent changes disclosed in 8-K filings.

All corporate leadership details for Jaguar Health should be verified in the company’s latest proxy statement and Form 10-K.

Stock information and listing

Ticker and exchange: jagx stock trades under the ticker JAGX on the Nasdaq stock market.
Classification: Jaguar Health is commonly classified as a micro-cap company. Micro-cap classification reflects a relatively low market capitalization compared with mid-cap and large-cap firms and often implies elevated volatility and liquidity considerations for jagx stock.
Trading hours: U.S. market hours (regular session) apply to JAGX as a Nasdaq-listed security; pre-market and after-hours trading may also occur through authorized brokers.
Identifiers: ISIN and FIGI codes for Jaguar Health are available on exchange and market-data platforms and in the company’s filings.
Shares outstanding and float: The company’s total shares outstanding and the publicly tradable float are published in the latest 10-Q/10-K and reported on market-data sites. Changes from financing, warrants, or reverse splits can materially change the share count and therefore jagx stock capitalization.

Investors should consult the company’s most recent SEC filings and Nasdaq’s company page for up-to-date share counts and outstanding securities that affect jagx stock.

Market capitalization and price history

As of Jan 26, 2026, jagx stock is characterized by a relatively small market capitalization consistent with a micro-cap profile. Market-cap figures for micro-cap companies can fluctuate widely with small absolute changes in share price because of the low share base. Historical price performance for jagx stock includes periods of heightened volatility around clinical updates, licensing announcements, financings, and retail community interest.

Notable historical considerations for jagx stock include:

Past intraday and multi-day price swings following company press releases or market commentary.
Occasional spikes in volume correlated with social-media attention and biotech sector movements.

For precise historical highs, lows, and percentage performance across YTD, 1-year, or multi-year windows, consult time-series data from market-data providers such as Yahoo Finance, Nasdaq, Finviz, and TradingView.

Trading statistics

Typical trading statistics investors examine for jagx stock include:

Average daily volume: Micro-cap stocks like JAGX can have variable average daily volumes, sometimes ranging from tens of thousands to several hundred thousand shares depending on market conditions and news flow.
Bid/ask spreads: JAGX may exhibit wider bid/ask spreads compared with large-cap stocks; wider spreads increase effective transaction costs when trading jagx stock.
Volatility metrics: Beta, average true range (ATR), and implied volatility (from options, if listed) provide measures of jagx stock’s risk characteristics. Micro-cap biotech equities often show above-market beta due to binary catalysts and liquidity constraints.

Market-data vendors (e.g., Yahoo Finance, Nasdaq, Finviz, TradingView) publish current volume and volatility metrics for jagx stock.

Share structure and ownership

Insider ownership: Executives and board members commonly hold notable stakes that are publicly disclosed. High insider ownership can indicate alignment with shareholders but may also reduce the freely tradable float, affecting the liquidity of jagx stock.
Institutional ownership: Institutional holdings in micro-cap names are typically smaller in percentage terms compared to larger companies; institutional investor disclosures can change after filings and quarter-ends.
Restricted vs. free float: Warrants, restricted shares, and convertible securities can constrain or expand the effective float when exercised or released, creating potential dilution events that influence jagx stock.

Recent insider transactions, equity financings, or warrant exercises are reported in Form 4s and 8-Ks and should be reviewed to understand changes to jagx stock’s ownership dynamics.

Financials

Jaguar Health’s financial profile as a small-cap biotech typically features modest product revenue, research and development expenses, and periodic net losses while the company funds operations and clinical development. Key financial metrics to review for jagx stock include:

Revenue: The company reports product sales and licensing revenue (when applicable) in quarterly and annual filings.
Profitability: Net income or loss, gross margin on product sales, and operating expenses determine the company’s near-term cash consumption.
Liquidity: Cash and short-term investments, current ratio, and the company’s disclosed cash runway are crucial for judging whether the company will need to raise capital — an event that can dilute jagx stock.
Debt: Debt levels, convertible notes, and financing terms should be noted for their potential effect on capital structure.

Where to find details: Jaguar Health’s annual report (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) provide audited and unaudited financial data. Analysts and market-data services then compute ratios such as P/S and debt/equity. For micro-cap biotech companies, price/earnings (P/E) ratios may be meaningless when companies report continued net losses.

Recent corporate events and news (selected reports)

Below are representative categories of corporate events and typical items that materially affect jagx stock sentiment. For each item, confirm dates and details in the cited sources and SEC filings.

Licensing and partnership agreements: Jaguar Health has announced licensing or distribution arrangements for crofelemer in various territories in the past. Such agreements can generate milestone or royalty revenue that materially influences jagx stock. As of Jan 26, 2026, consult the company’s press releases and Nasdaq company page for the latest reported deals.
Clinical trial updates and regulatory interactions: Positive or negative data from trials of crofelemer in new indications, or regulatory feedback from agencies (e.g., FDA), are binary events for jagx stock and are typically reported by the company and covered by health-care media outlets.
Financing and capital raises: Periodic equity or debt financings to support operations can cause dilution and short-term pressure on jagx stock. Filings for registered direct offerings, At-The-Market (ATM) programs, and convertibles should be reviewed.
Corporate actions to maintain listing compliance: Nasdaq may require companies to maintain minimum bid prices or shareholder-equity thresholds. Jaguar Health has taken or may take actions such as reverse stock splits or other measures to comply; these actions affect jagx stock arithmetic.
Patent and IP developments: Grants, approvals, or expirations related to crofelemer’s intellectual property can affect long-term commercial prospects and jagx stock valuation.

Examples of news reporting: As of Jan 26, 2026, major market-data providers and business media (e.g., Yahoo Finance, Nasdaq’s investor page, CNBC, and TradingView community notes) have covered Jaguar Health corporate updates. For precise press-release dates and financing amounts, consult the company’s press releases filed via SEC Form 8-K and verify with market-data aggregators.

Clinical and regulatory status

Jaguar Health’s clinical and regulatory story centers on crofelemer (Mytesi) and any trial programs seeking label expansion or new indications. Points to monitor for jagx stock include:

Trial phase and endpoints: Whether studies are preclinical, Phase 1–3, or post-marketing studies — and whether endpoints are symptomatic relief, biomarker changes, or harder clinical outcomes.
Regulatory designations: Fast Track, Orphan Drug, Breakthrough Therapy, and similar FDA or international agency designations materially affect development timelines.
Approvals and label updates: Any new approvals or label expansions for crofelemer-based products are material to jagx stock and are announced via press releases and regulatory databases.

Clinical progress and regulatory interactions are the most common short-term catalysts for jagx stock, and trial results are typically covered by industry press and market-data platforms.

Investment considerations and risks

The following risks are common and relevant for anyone researching jagx stock. This section presents neutral, factual considerations — not investment advice.

Biotech and clinical risk: Clinical trials can fail or yield inconclusive results; regulatory approval is not guaranteed. For jagx stock, development outcomes for crofelemer's expanded indications are binary drivers.
Micro-cap and penny-stock risk: As a micro-cap, jagx stock may have limited liquidity, wider bid/ask spreads, and more pronounced price swings. Smaller market caps mean news or small-volume trades can move the share price significantly.
Dilution risk: Small pharmaceutical companies often raise capital through equity offerings, which can dilute existing jagx stockholders’ percentage ownership.
Concentration risk: Dependence on a small number of products (e.g., crofelemer/Mytesi and selected animal-health candidates) creates revenue concentration that can increase risk if a product underperforms or loses exclusivity.
Market and sector risk: Changes in investor sentiment toward small-cap biotech stocks or broader market corrections can disproportionately affect jagx stock.

Investors evaluating jagx stock should review SEC filings, study trial protocols and endpoints, and consider liquidity and corporate-finance risks.

Analyst coverage and market sentiment

Analyst coverage: Micro-cap companies like Jaguar Health may have limited sell-side analyst coverage. Publicly available price targets and sell/hold/buy recommendations, if present, are typically summarized on market-data platforms.
Retail and social sentiment: jagx stock often appears in retail-investor discussions on social platforms and trading communities; these conversations can influence intraday volumes and short-term volatility. Platforms such as StockTwits and TradingView host active user commentaries and chart-based sentiment, which traders sometimes reference.
Media coverage: Business outlets (e.g., CNBC, CNN Markets) and financial-data aggregators (Yahoo Finance, Finviz) occasionally cover corporate news that move jagx stock.

When assessing sentiment, separate short-term social-media-driven momentum from fundamental, long-term company developments present in SEC filings and peer-reviewed clinical data.

Legal, regulatory and compliance matters

Jaguar Health’s material legal and compliance matters are disclosed in periodic filings. Areas to watch for jagx stock include:

SEC reporting: Timely filing of 10-Ks, 10-Qs, and 8-Ks is required. Delays or restatements can negatively affect jagx stock.
Nasdaq compliance: The company must meet Nasdaq listing standards (e.g., minimum bid price, market value of publicly held shares, and timely reporting). Companies may announce reverse splits or other corrective actions to regain compliance; such corporate actions can materially change jagx stock statistics.
Litigation and contingency disclosures: Any significant legal claims or contingent liabilities are described in annual and quarterly filings and may affect valuation and risk perceptions.

All material legal/regulatory events are reported in the company’s SEC filings and press releases that investors should consult.

Historical corporate actions

Jaguar Health’s capital-structure history may include:

Past financings: Registered offerings, private placements, and shelf filings that raised capital and generated dilution impacting jagx stock.
Warrants and convertible instruments: Instruments that may convert into common stock and therefore affect future float and supply.
Reverse splits: Actions to meet listing requirements or manage per-share arithmetic; reverse splits reduce share count but do not inherently increase market capitalization. Announcements of splits or reverse splits are material for jagx stock.

Historical corporate action details are available in the company’s SEC filing history and summarized on exchange and market-data pages.

How to monitor jagx stock (practical checklist)

For researchers and traders tracking jagx stock, use this checklist:

Check the latest SEC filings (10-K, 10-Q, 8-K) for audited financials, material events, and management commentary.
Review recent press releases for licensing deals, trial results, and corporate actions that can move jagx stock.
Consult live market-data pages (Yahoo Finance, Nasdaq, TradingView) for current price, volume, and volatility metrics.
Scan social and trading communities (StockTwits, TradingView ideas) for retail sentiment but treat community commentary as supplemental to primary sources.
Monitor Nasdaq compliance notices and Form 4 insider transactions to understand insider behavior that can influence jagx stock liquidity and float.
Track analyst notes (if any) and specialized biotechnology news coverage for third-party perspectives.

If you trade or plan to trade jagx stock, choose a broker or trading venue you trust. For users of Bitget, consider Bitget’s trading services where available and consult Bitget Wallet for custody options. Confirm whether Bitget supports U.S.-listed equities in your region and follow all local regulatory and platform requirements.

References (selected sources)

Yahoo Finance (JAGX quote pages and company profile) — market data and trading statistics (As of Jan 26, 2026)
Nasdaq company page — listing details and corporate disclosures (As of Jan 26, 2026)
CNBC and CNN Markets — occasional coverage of corporate events and market context (recent reports as indexed on provider pages; check publication dates on each article)
Finviz and TradingView — charting, historical prices, volatility measures and community ideas
StockTwits — retail sentiment and message-board activity around jagx stock
Robinhood and Webull (quote pages) — retail-facing overviews and trading stats
Company SEC filings (10-K, 10-Q, 8-K) and official press releases — authoritative source for financials, governance, and clinical/regulatory updates

Note: For each material fact (e.g., market cap, outstanding shares, clinical trial status), consult the primary SEC filing or the company’s official press releases for confirmation and the exact date-stamped disclosure.